Phosphatidylinositol 4,5-bisphosphate-specific AKT1 is oncogenic

Activating E17K mutation in the gene encoding the protein kinase AKT in a subset of squamous cell carcinoma of the lung

(2010) Donatella Malanga et al.   CELL CYCLE

The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas

(2009) K Shoji et al.   BRITISH JOURNAL OF CANCER

PIKKing on PKB: regulation of PKB activity by phosphorylation

(2009) Lana Bozulic et al.   CURRENT OPINION IN CELL BIOLOGY

Inhibitor hijacking of Akt activation

(2009) Tatsuya Okuzumi et al.   Nature Chemical Biology

A distinct pool of phosphatidylinositol 4,5-bisphosphate in caveolae revealed by a nanoscale labeling technique

(2009) A. Fujita et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A new evaluation method for quantifying PI3K activity by HTRF assay

(2008) Hironobu Sugita et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Effects of oncogenic p110α subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase

(2008) Jeffrey D. Carson et al.   BIOCHEMICAL JOURNAL

Molecular Mechanism of an Oncogenic Mutation That Alters Membrane Targeting: Glu17Lys Modifies the PIP Lipid Specificity of the AKT1 PH Domain†

(2008) Kyle E. Landgraf et al.   BIOCHEMISTRY

Targeting the PI3K–AKT–mTOR pathway: progress, pitfalls, and promises

(2008) Timothy A Yap et al.   CURRENT OPINION IN PHARMACOLOGY

Class IA phosphatidylinositol 3-kinase: from their biologic implication in human cancers to drug discovery

(2008) Sauveur-Michel Maira et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Lipid signalling in disease

(2008) Matthias P. Wymann et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Drug discovery approaches targeting the PI3K/Akt pathway in cancer

(2008) C Garcia-Echeverria et al.   ONCOGENE